MeiraGTx Holdings PLC
MGTX6.610USD
+0.120+1.85%
交易中 （美東）報價延遲15分鐘
518.21M總市值
虧損本益比TTM
關於 MeiraGTx Holdings PLC 公司
MeiraGTx Holdings PLC 是一家垂直整合的臨牀階段基因治療公司。該公司專注於三個不同的未滿足醫療需求領域：眼部疾病，包括遺傳性視網膜疾病 (IRD) 以及大型退行性眼部疾病、嚴重形式的口乾症和神經退行性疾病。其產品線包括 botaretigene sparoparvovec 或 bota-vec，用於治療與視網膜色素變性 GTPase 調節基因或 XLRP-RPGR 突變相關的 X 連鎖視網膜色素變性；AAV-hAQP1，用於治療放射引起的 2/3 級口乾症；AAV-hAQP1，用於治療乾燥綜合徵；AAV-GAD，用於治療帕金森病；AAV-RPE65，用於治療 RPE65 相關視網膜營養不良； AAV-CNGB3 和 AAV-CNGA3 用於治療全色盲；AAV-AIPL1 用於治療 LCA4，AAV-RDH12 用於治療 RDH12 突變相關的視網膜營養不良。
公司簡介
公司代碼MGTX
公司名稱MeiraGTx Holdings PLC
上市日期Jun 08, 2018
成立日期2018
CEODr. Alexandria Forbes, Ph.D.
員工數量381
證券類型Ordinary Share
年結日Jun 08
公司地址450 East 29Th Street
城市NEW YORK
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編10016
電話16468607985
網址https://meiragtx.com/
公司代碼MGTX
上市日期Jun 08, 2018
成立日期2018
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.41M
-3.26%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
972.65K
-2.41%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
+4.44%
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
50.00K
+150.00%
Amb. Martin Indyk, Ph.D.
Amb. Martin Indyk, Ph.D.
Independent Director
Independent Director
35.00K
+133.33%
Mr. Robert J. Wollin, J.D.
Mr. Robert J. Wollin, J.D.
General Counsel, Secretary
General Counsel, Secretary
31.15K
+50.01%
Ms. Ellen Hukkelhoven, Ph.D.
Ms. Ellen Hukkelhoven, Ph.D.
Independent Director
Independent Director
--
--
Ms. Nicole Seligman
Ms. Nicole Seligman
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.41M
-3.26%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
972.65K
-2.41%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
+4.44%
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
50.00K
+150.00%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 4月11日 週五
更新時間: 4月11日 週五
持股股東
股東類型
持股股東
股東統計
佔比
Perceptive Advisors LLC
15.95%
Sanofi
15.47%
Johnson & Johnson Innovation-JJDC, Inc.
8.42%
Adage Capital Management, L.P.
6.38%
Prosight Capital
5.57%
Other
48.20%
持股股東
股東統計
佔比
Perceptive Advisors LLC
15.95%
Sanofi
15.47%
Johnson & Johnson Innovation-JJDC, Inc.
8.42%
Adage Capital Management, L.P.
6.38%
Prosight Capital
5.57%
Other
48.20%
股東類型
股東統計
佔比
Hedge Fund
20.60%
Corporation
20.50%
Private Equity
15.95%
Venture Capital
8.42%
Investment Advisor
7.03%
Investment Advisor/Hedge Fund
5.71%
Individual Investor
4.36%
Research Firm
1.07%
Bank and Trust
0.09%
Other
16.28%
機構持股
更新時間: 3月4日 週二
更新時間: 3月4日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
230
77.61M
98.43%
+22.67M
2024Q4
246
77.41M
99.87%
+22.10M
2024Q3
250
64.74M
84.14%
+9.72M
2024Q2
251
52.33M
80.03%
+4.22M
2024Q1
254
51.24M
78.85%
+2.58M
2023Q4
253
50.76M
80.27%
+3.66M
2023Q3
255
41.86M
71.40%
-5.70M
2023Q2
256
41.99M
71.79%
-2.93M
2023Q1
256
32.89M
67.58%
-5.40M
2022Q4
257
33.39M
69.27%
-47.74K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Perceptive Advisors LLC
12.58M
15.95%
--
--
Dec 31, 2024
Sanofi
12.20M
15.47%
+12.20M
--
Dec 31, 2024
Johnson & Johnson Innovation-JJDC, Inc.
6.64M
8.42%
--
--
Dec 31, 2024
Adage Capital Management, L.P.
5.03M
6.38%
-194.52K
-3.72%
Dec 31, 2024
Prosight Capital
4.39M
5.57%
-509.73K
-10.40%
Dec 31, 2024
Adena Estate Inc.
3.27M
4.14%
+3.27M
--
Dec 31, 2023
BlackRock Institutional Trust Company, N.A.
2.64M
3.35%
+278.31K
+11.79%
Dec 31, 2024
683 Capital Management LLC
2.42M
3.06%
-135.00K
-5.29%
Dec 31, 2024
Woodline Partners LP
1.54M
1.95%
+1.54M
--
Dec 31, 2024
Forbes (Alexandria)
1.46M
1.85%
+58.91K
+4.21%
Feb 21, 2025
查看更多
持股ETF
更新時間: 4月6日 週日
更新時間: 4月6日 週日
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0.54%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.03%
SPDR S&P International Small Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
查看更多
Invesco NASDAQ Future Gen 200 ETF
佔比0.54%
iShares Micro-Cap ETF
佔比0.07%
ProShares Ultra Nasdaq Biotechnology
佔比0.05%
Invesco Nasdaq Biotechnology ETF
佔比0.05%
iShares Biotechnology ETF
佔比0.03%
SPDR S&P International Small Cap ETF
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.01%
iShares Russell 2000 Growth ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據